Canaccord reiterates a Sell on Seattle Genetics (SGEN -3.2%) after its unwillingness to provide...

Canaccord reiterates a Sell on Seattle Genetics (SGEN -3.2%) after its unwillingness to provide 2012 sales guidance for Adcetris in tandem with its Q4 report spooks investors. The firm sees "a number of factors" hurting Adcetris sales this year, including sales adjustments, the near-exhaustion of a patient pool treated last year, and the negative impact on treatment duration from a change in treatment approach.

From other sites
Comments (1)
  • mikeurl
    , contributor
    Comments (745) | Send Message
    The recent results on their investigational trials have been a little bit short of miraculous. But not that far short. They have been curing a significant number of relapsed patients. Hard cases that really are only allowed to even participate because all other treatment options are ruled out. To get measurable response in 60% of a population like that is, as far as I can tell, hugely positive. Their other front-line trials are going absurdly well. Also, as they scan all cancers for cd positive receptors this has the potential to mushroom.


    Granted, adcetris isn't taking off like a rocket. Then again it is very very expensive and the process of getting insurers to pay sounds arduous and clinical trials are like walking through mud with lead boots takes time.
    14 Feb 2012, 12:06 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs